APA (7th ed.) Citation

Garcia-Manero, G., Montalban-Bravo, G., Yang, H., Wei, Y., Alvarado, Y., DiNardo, C. D., . . . Reilly, M. (2016). A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy. Blood, 128(22), 227. https://doi.org/10.1182/blood.V128.22.227.227

Chicago Style (17th ed.) Citation

Garcia-Manero, Guillermo, et al. "A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy." Blood 128, no. 22 (2016): 227. https://doi.org/10.1182/blood.V128.22.227.227.

MLA (9th ed.) Citation

Garcia-Manero, Guillermo, et al. "A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy." Blood, vol. 128, no. 22, 2016, p. 227, https://doi.org/10.1182/blood.V128.22.227.227.